Genentech

Parent Organization: Roche Holdings

Genentech Inc., or Genetic Engineering Technology, Inc., is a biotechnology corporation, founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert Boyer. It is considered to have founded the biotechnology industry. One of its founders, Boyer, is considered to be a pioneer in the field of recombinant DNA technology. In 1973, Boyer and his colleague Stanley Norman Cohen demonstrated that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia, Swanson contacted Boyer to found the company. Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977. David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin in 1978.

Source: Wikipedia

Campaign Finance

$92,720 Given
Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

covers through 2011

  • Top Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.

  • Republicans vs. Democrats

    in dollars

  • State vs. Federal

    in dollars

  • Top PAC Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for Genentech Sources: OpenSecrets.org FollowTheMoney.org

Regulations

15 Mentions; 2 Submissions
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated from Regulations.gov on September 27, 2011

The tables show occurrences of "Genentech" in public comments on proposed federal regulations.

  • Documents Submitted by the Organization
    • Submissions
    • Agency
    • Docket
    • Date
    • Toggle 1 FDA Draft Guidance for Industry on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies; Availability 2011
    • Toggle 1 HRSA Exclusion of Orphan Drugs for Certain Covered Entities under 340B Program 2011
  • Mentions in Document Text
    • Mentions
    • Agency
    • Docket
    • Date
    • Toggle 2 FDA Periodic Review of Existing Regulations; Retrospective Review Under Executive Order 13563 2011
    • Toggle 2 HRSA Exclusion of Orphan Drugs for Certain Covered Entities under 340B Program 2011
    • Toggle 1 CMS Medicare Program; Changes to the End-Stage Renal Disease Prospective Payment System for CY 2012, End-Stage Renal Disease Quality Incentive Program for PY 2013 and PY 2014; Ambulance Fee Schedule; and Durable Medical Equipment 2011
    • Toggle 1 FDA Draft Guidance for Industry on Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics; Availability 2011
    • Toggle 1 CMS Methods for Assuring Access to Covered Medicaid Services (CMS-2328-P) 2011
    • Toggle 1 FDA Draft Guidance for Industry and Food and Drug Administration Staff; Establishing the Performance Characteristics of In Vitro Diagnostic Devices for Chlamydia trachomatis and/or Neisseria gonorrhoea: Screening and Diagnostic Testing 2011
    • Toggle 1 CMS Hospital Outpatient Prospective Payment; Ambulatory Surgical Center Payment; Hospital Value-Based Purchasing Program; Physician Self-Referral; and Provider Agreement Regulations on Patient Notification Requirements 2011
    • Toggle 1 CMS Medicare and Medicaid Programs; Opportunities for Alignment under Medicaid and Medicare (CMS-5507-NC) 2011
    • Toggle 1 FDA Draft Guidance for Industry on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies; Availability 2011
    • Toggle 1 CMS Medicare & Medicaid: Influenza Vaccination Standard for Certain Medicare & Medicaid Participating Providers and Suppliers 2011